BMO Capital Starts NewAmsterdam Pharma Co NV (NAMS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts NAMS Hot Sheet
Price: $21.58 +1.51%
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
BMO Capital initiates coverage on NewAmsterdam Pharma Co NV (NASDAQ: NAMS) with a Outperform rating and a price target of $58.00.
For an analyst ratings summary and ratings history on NewAmsterdam Pharma Co NV click here. For more ratings news on NewAmsterdam Pharma Co NV click here.
Shares of NewAmsterdam Pharma Co NV closed at $31.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: just concluded a highly successful discussion with president Vladimir Putin
- GTCR and Elliott nearing deal for CCC Intelligent Solutions - Bloomberg
- RBC on Semiconductor short interest as of September 30th
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
BMO Capital, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
